Retatrutide is a high-quality research peptide that is attracting worldwide attention due to its innovative triple action on the GLP-1 , GIP and glucagon receptors
Emerging alternatives and next-generation treatments The GLP-1 space is evolving rapidly
Original Medicare (Parts A and B) doesnt cover most outpatient prescription drugs
Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al
Nevertheless, the team did emphasize that the short follow-up period in their study may be insufficient to fully capture the chronic trajectory of glaucoma development, particularly given the recent FDA approval of tirzepatide
4 Medication costs are separate and may be covered under the customers HSA and FSA plan
